Loading…

Aurora A kinase inhibition induces accumulation of SCLC tumor cells in mitosis with restored interferon signaling to increase response to PD-L1

Despite small cell lung cancers (SCLCs) having a high mutational burden, programmed death-ligand 1 (PD-L1) immunotherapy only modestly increases survival. A subset of SCLCs that lose their ASCL1 neuroendocrine phenotype and restore innate immune signaling (termed the "inflammatory" subtype...

Full description

Saved in:
Bibliographic Details
Published in:Cell reports. Medicine 2023-11, Vol.4 (11), p.101282, Article 101282
Main Authors: Li, Yixiang, Mahadevan, Navin R, Duplaquet, Leslie, Hong, Deli, Durmaz, Yavuz T, Jones, Kristen L, Cho, Hyeonseo, Morrow, Murry, Protti, Andrea, Poitras, Michael J, Springer, Benjamin F, Bronson, Roderick T, Gong, Xueqian, Hui, Yu-Hua, Du, Jian, Southard, Jackson, Thai, Tran, Li, Shuqiang, Lizotte, Patrick H, Gokhale, Prafulla C, Nguyen, Quang-De, Oser, Matthew G
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c403t-9c2af0bd86def727b373a14e1bf829342b4df650cc2ce5aed82e7cdb08a6441d3
cites cdi_FETCH-LOGICAL-c403t-9c2af0bd86def727b373a14e1bf829342b4df650cc2ce5aed82e7cdb08a6441d3
container_end_page
container_issue 11
container_start_page 101282
container_title Cell reports. Medicine
container_volume 4
creator Li, Yixiang
Mahadevan, Navin R
Duplaquet, Leslie
Hong, Deli
Durmaz, Yavuz T
Jones, Kristen L
Cho, Hyeonseo
Morrow, Murry
Protti, Andrea
Poitras, Michael J
Springer, Benjamin F
Bronson, Roderick T
Gong, Xueqian
Hui, Yu-Hua
Du, Jian
Southard, Jackson
Thai, Tran
Li, Shuqiang
Lizotte, Patrick H
Gokhale, Prafulla C
Nguyen, Quang-De
Oser, Matthew G
description Despite small cell lung cancers (SCLCs) having a high mutational burden, programmed death-ligand 1 (PD-L1) immunotherapy only modestly increases survival. A subset of SCLCs that lose their ASCL1 neuroendocrine phenotype and restore innate immune signaling (termed the "inflammatory" subtype) have durable responses to PD-L1. Some SCLCs are highly sensitive to Aurora kinase inhibitors, but early-phase trials show short-lived responses, suggesting effective therapeutic combinations are needed to increase their durability. Using immunocompetent SCLC genetically engineered mouse models (GEMMs) and syngeneic xenografts, we show durable efficacy with the combination of a highly specific Aurora A kinase inhibitor (LSN3321213) and PD-L1. LSN3321213 causes accumulation of tumor cells in mitosis with lower ASCL1 expression and higher expression of interferon target genes and antigen-presentation genes mimicking the inflammatory subtype in a cell-cycle-dependent manner. These data demonstrate that inflammatory gene expression is restored in mitosis in SCLC, which can be exploited by Aurora A kinase inhibition.
doi_str_mv 10.1016/j.xcrm.2023.101282
format article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10694667</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2892948544</sourcerecordid><originalsourceid>FETCH-LOGICAL-c403t-9c2af0bd86def727b373a14e1bf829342b4df650cc2ce5aed82e7cdb08a6441d3</originalsourceid><addsrcrecordid>eNpVUc2OFCEYJEbjbtZ9AQ-Go5ce-RuaPpnJqKvJJJqoZ0LD1zOM3TAC7c9T7CtLO-tmPVGpr6o-oBB6TsmKEipfHVe_bJpWjDC-EEyxR-iSSSkb3nb08QN8ga5zPhJC2JpSxclTdFHpjkmlLtHtZk4xGbzB33wwGbAPB9_74mOo0M0WMjbWztM8mr9kHPDn7W6LyzzFhC2MY65CPPkSs8_4py8HnCCXmMDVQYE0QKq-7PfBjD7scYmVtwmWbVV5iqGCSn560-zoM_RkMGOG67vzCn199_bL9n2z-3jzYbvZNVYQXprOMjOQ3inpYGhZ2_OWGyqA9oNiHResF26Qa2Its7A24BSD1rqeKCOFoI5fodfn3NPcT-AshJLMqE_JTyb91tF4_f8k-IPexx-aEtkJKdua8PIuIcXvc32xnnxe_sMEiHPWTHWsE2otRJWys9SmmHOC4X4PJXppUx_10qZe2tTnNqvpxcMb3lv-dcf_ABBmoJA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2892948544</pqid></control><display><type>article</type><title>Aurora A kinase inhibition induces accumulation of SCLC tumor cells in mitosis with restored interferon signaling to increase response to PD-L1</title><source>ScienceDirect</source><source>Open Access: PubMed Central</source><creator>Li, Yixiang ; Mahadevan, Navin R ; Duplaquet, Leslie ; Hong, Deli ; Durmaz, Yavuz T ; Jones, Kristen L ; Cho, Hyeonseo ; Morrow, Murry ; Protti, Andrea ; Poitras, Michael J ; Springer, Benjamin F ; Bronson, Roderick T ; Gong, Xueqian ; Hui, Yu-Hua ; Du, Jian ; Southard, Jackson ; Thai, Tran ; Li, Shuqiang ; Lizotte, Patrick H ; Gokhale, Prafulla C ; Nguyen, Quang-De ; Oser, Matthew G</creator><creatorcontrib>Li, Yixiang ; Mahadevan, Navin R ; Duplaquet, Leslie ; Hong, Deli ; Durmaz, Yavuz T ; Jones, Kristen L ; Cho, Hyeonseo ; Morrow, Murry ; Protti, Andrea ; Poitras, Michael J ; Springer, Benjamin F ; Bronson, Roderick T ; Gong, Xueqian ; Hui, Yu-Hua ; Du, Jian ; Southard, Jackson ; Thai, Tran ; Li, Shuqiang ; Lizotte, Patrick H ; Gokhale, Prafulla C ; Nguyen, Quang-De ; Oser, Matthew G</creatorcontrib><description>Despite small cell lung cancers (SCLCs) having a high mutational burden, programmed death-ligand 1 (PD-L1) immunotherapy only modestly increases survival. A subset of SCLCs that lose their ASCL1 neuroendocrine phenotype and restore innate immune signaling (termed the "inflammatory" subtype) have durable responses to PD-L1. Some SCLCs are highly sensitive to Aurora kinase inhibitors, but early-phase trials show short-lived responses, suggesting effective therapeutic combinations are needed to increase their durability. Using immunocompetent SCLC genetically engineered mouse models (GEMMs) and syngeneic xenografts, we show durable efficacy with the combination of a highly specific Aurora A kinase inhibitor (LSN3321213) and PD-L1. LSN3321213 causes accumulation of tumor cells in mitosis with lower ASCL1 expression and higher expression of interferon target genes and antigen-presentation genes mimicking the inflammatory subtype in a cell-cycle-dependent manner. These data demonstrate that inflammatory gene expression is restored in mitosis in SCLC, which can be exploited by Aurora A kinase inhibition.</description><identifier>ISSN: 2666-3791</identifier><identifier>EISSN: 2666-3791</identifier><identifier>DOI: 10.1016/j.xcrm.2023.101282</identifier><identifier>PMID: 37992688</identifier><language>eng</language><publisher>United States: Elsevier</publisher><subject>Animals ; Aurora Kinase A - genetics ; Aurora Kinase A - therapeutic use ; B7-H1 Antigen - genetics ; Humans ; Interferons - genetics ; Lung Neoplasms - drug therapy ; Lung Neoplasms - genetics ; Lung Neoplasms - pathology ; Mice ; Mitosis ; Small Cell Lung Carcinoma - drug therapy ; Small Cell Lung Carcinoma - genetics ; Small Cell Lung Carcinoma - pathology</subject><ispartof>Cell reports. Medicine, 2023-11, Vol.4 (11), p.101282, Article 101282</ispartof><rights>Copyright © 2023 The Author(s). Published by Elsevier Inc. All rights reserved.</rights><rights>2023 The Author(s) 2023</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c403t-9c2af0bd86def727b373a14e1bf829342b4df650cc2ce5aed82e7cdb08a6441d3</citedby><cites>FETCH-LOGICAL-c403t-9c2af0bd86def727b373a14e1bf829342b4df650cc2ce5aed82e7cdb08a6441d3</cites><orcidid>0000-0003-2047-0969</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10694667/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10694667/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27923,27924,53790,53792</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/37992688$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Li, Yixiang</creatorcontrib><creatorcontrib>Mahadevan, Navin R</creatorcontrib><creatorcontrib>Duplaquet, Leslie</creatorcontrib><creatorcontrib>Hong, Deli</creatorcontrib><creatorcontrib>Durmaz, Yavuz T</creatorcontrib><creatorcontrib>Jones, Kristen L</creatorcontrib><creatorcontrib>Cho, Hyeonseo</creatorcontrib><creatorcontrib>Morrow, Murry</creatorcontrib><creatorcontrib>Protti, Andrea</creatorcontrib><creatorcontrib>Poitras, Michael J</creatorcontrib><creatorcontrib>Springer, Benjamin F</creatorcontrib><creatorcontrib>Bronson, Roderick T</creatorcontrib><creatorcontrib>Gong, Xueqian</creatorcontrib><creatorcontrib>Hui, Yu-Hua</creatorcontrib><creatorcontrib>Du, Jian</creatorcontrib><creatorcontrib>Southard, Jackson</creatorcontrib><creatorcontrib>Thai, Tran</creatorcontrib><creatorcontrib>Li, Shuqiang</creatorcontrib><creatorcontrib>Lizotte, Patrick H</creatorcontrib><creatorcontrib>Gokhale, Prafulla C</creatorcontrib><creatorcontrib>Nguyen, Quang-De</creatorcontrib><creatorcontrib>Oser, Matthew G</creatorcontrib><title>Aurora A kinase inhibition induces accumulation of SCLC tumor cells in mitosis with restored interferon signaling to increase response to PD-L1</title><title>Cell reports. Medicine</title><addtitle>Cell Rep Med</addtitle><description>Despite small cell lung cancers (SCLCs) having a high mutational burden, programmed death-ligand 1 (PD-L1) immunotherapy only modestly increases survival. A subset of SCLCs that lose their ASCL1 neuroendocrine phenotype and restore innate immune signaling (termed the "inflammatory" subtype) have durable responses to PD-L1. Some SCLCs are highly sensitive to Aurora kinase inhibitors, but early-phase trials show short-lived responses, suggesting effective therapeutic combinations are needed to increase their durability. Using immunocompetent SCLC genetically engineered mouse models (GEMMs) and syngeneic xenografts, we show durable efficacy with the combination of a highly specific Aurora A kinase inhibitor (LSN3321213) and PD-L1. LSN3321213 causes accumulation of tumor cells in mitosis with lower ASCL1 expression and higher expression of interferon target genes and antigen-presentation genes mimicking the inflammatory subtype in a cell-cycle-dependent manner. These data demonstrate that inflammatory gene expression is restored in mitosis in SCLC, which can be exploited by Aurora A kinase inhibition.</description><subject>Animals</subject><subject>Aurora Kinase A - genetics</subject><subject>Aurora Kinase A - therapeutic use</subject><subject>B7-H1 Antigen - genetics</subject><subject>Humans</subject><subject>Interferons - genetics</subject><subject>Lung Neoplasms - drug therapy</subject><subject>Lung Neoplasms - genetics</subject><subject>Lung Neoplasms - pathology</subject><subject>Mice</subject><subject>Mitosis</subject><subject>Small Cell Lung Carcinoma - drug therapy</subject><subject>Small Cell Lung Carcinoma - genetics</subject><subject>Small Cell Lung Carcinoma - pathology</subject><issn>2666-3791</issn><issn>2666-3791</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><recordid>eNpVUc2OFCEYJEbjbtZ9AQ-Go5ce-RuaPpnJqKvJJJqoZ0LD1zOM3TAC7c9T7CtLO-tmPVGpr6o-oBB6TsmKEipfHVe_bJpWjDC-EEyxR-iSSSkb3nb08QN8ga5zPhJC2JpSxclTdFHpjkmlLtHtZk4xGbzB33wwGbAPB9_74mOo0M0WMjbWztM8mr9kHPDn7W6LyzzFhC2MY65CPPkSs8_4py8HnCCXmMDVQYE0QKq-7PfBjD7scYmVtwmWbVV5iqGCSn560-zoM_RkMGOG67vzCn199_bL9n2z-3jzYbvZNVYQXprOMjOQ3inpYGhZ2_OWGyqA9oNiHResF26Qa2Its7A24BSD1rqeKCOFoI5fodfn3NPcT-AshJLMqE_JTyb91tF4_f8k-IPexx-aEtkJKdua8PIuIcXvc32xnnxe_sMEiHPWTHWsE2otRJWys9SmmHOC4X4PJXppUx_10qZe2tTnNqvpxcMb3lv-dcf_ABBmoJA</recordid><startdate>20231121</startdate><enddate>20231121</enddate><creator>Li, Yixiang</creator><creator>Mahadevan, Navin R</creator><creator>Duplaquet, Leslie</creator><creator>Hong, Deli</creator><creator>Durmaz, Yavuz T</creator><creator>Jones, Kristen L</creator><creator>Cho, Hyeonseo</creator><creator>Morrow, Murry</creator><creator>Protti, Andrea</creator><creator>Poitras, Michael J</creator><creator>Springer, Benjamin F</creator><creator>Bronson, Roderick T</creator><creator>Gong, Xueqian</creator><creator>Hui, Yu-Hua</creator><creator>Du, Jian</creator><creator>Southard, Jackson</creator><creator>Thai, Tran</creator><creator>Li, Shuqiang</creator><creator>Lizotte, Patrick H</creator><creator>Gokhale, Prafulla C</creator><creator>Nguyen, Quang-De</creator><creator>Oser, Matthew G</creator><general>Elsevier</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0003-2047-0969</orcidid></search><sort><creationdate>20231121</creationdate><title>Aurora A kinase inhibition induces accumulation of SCLC tumor cells in mitosis with restored interferon signaling to increase response to PD-L1</title><author>Li, Yixiang ; Mahadevan, Navin R ; Duplaquet, Leslie ; Hong, Deli ; Durmaz, Yavuz T ; Jones, Kristen L ; Cho, Hyeonseo ; Morrow, Murry ; Protti, Andrea ; Poitras, Michael J ; Springer, Benjamin F ; Bronson, Roderick T ; Gong, Xueqian ; Hui, Yu-Hua ; Du, Jian ; Southard, Jackson ; Thai, Tran ; Li, Shuqiang ; Lizotte, Patrick H ; Gokhale, Prafulla C ; Nguyen, Quang-De ; Oser, Matthew G</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c403t-9c2af0bd86def727b373a14e1bf829342b4df650cc2ce5aed82e7cdb08a6441d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Animals</topic><topic>Aurora Kinase A - genetics</topic><topic>Aurora Kinase A - therapeutic use</topic><topic>B7-H1 Antigen - genetics</topic><topic>Humans</topic><topic>Interferons - genetics</topic><topic>Lung Neoplasms - drug therapy</topic><topic>Lung Neoplasms - genetics</topic><topic>Lung Neoplasms - pathology</topic><topic>Mice</topic><topic>Mitosis</topic><topic>Small Cell Lung Carcinoma - drug therapy</topic><topic>Small Cell Lung Carcinoma - genetics</topic><topic>Small Cell Lung Carcinoma - pathology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Li, Yixiang</creatorcontrib><creatorcontrib>Mahadevan, Navin R</creatorcontrib><creatorcontrib>Duplaquet, Leslie</creatorcontrib><creatorcontrib>Hong, Deli</creatorcontrib><creatorcontrib>Durmaz, Yavuz T</creatorcontrib><creatorcontrib>Jones, Kristen L</creatorcontrib><creatorcontrib>Cho, Hyeonseo</creatorcontrib><creatorcontrib>Morrow, Murry</creatorcontrib><creatorcontrib>Protti, Andrea</creatorcontrib><creatorcontrib>Poitras, Michael J</creatorcontrib><creatorcontrib>Springer, Benjamin F</creatorcontrib><creatorcontrib>Bronson, Roderick T</creatorcontrib><creatorcontrib>Gong, Xueqian</creatorcontrib><creatorcontrib>Hui, Yu-Hua</creatorcontrib><creatorcontrib>Du, Jian</creatorcontrib><creatorcontrib>Southard, Jackson</creatorcontrib><creatorcontrib>Thai, Tran</creatorcontrib><creatorcontrib>Li, Shuqiang</creatorcontrib><creatorcontrib>Lizotte, Patrick H</creatorcontrib><creatorcontrib>Gokhale, Prafulla C</creatorcontrib><creatorcontrib>Nguyen, Quang-De</creatorcontrib><creatorcontrib>Oser, Matthew G</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Cell reports. Medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Li, Yixiang</au><au>Mahadevan, Navin R</au><au>Duplaquet, Leslie</au><au>Hong, Deli</au><au>Durmaz, Yavuz T</au><au>Jones, Kristen L</au><au>Cho, Hyeonseo</au><au>Morrow, Murry</au><au>Protti, Andrea</au><au>Poitras, Michael J</au><au>Springer, Benjamin F</au><au>Bronson, Roderick T</au><au>Gong, Xueqian</au><au>Hui, Yu-Hua</au><au>Du, Jian</au><au>Southard, Jackson</au><au>Thai, Tran</au><au>Li, Shuqiang</au><au>Lizotte, Patrick H</au><au>Gokhale, Prafulla C</au><au>Nguyen, Quang-De</au><au>Oser, Matthew G</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Aurora A kinase inhibition induces accumulation of SCLC tumor cells in mitosis with restored interferon signaling to increase response to PD-L1</atitle><jtitle>Cell reports. Medicine</jtitle><addtitle>Cell Rep Med</addtitle><date>2023-11-21</date><risdate>2023</risdate><volume>4</volume><issue>11</issue><spage>101282</spage><pages>101282-</pages><artnum>101282</artnum><issn>2666-3791</issn><eissn>2666-3791</eissn><abstract>Despite small cell lung cancers (SCLCs) having a high mutational burden, programmed death-ligand 1 (PD-L1) immunotherapy only modestly increases survival. A subset of SCLCs that lose their ASCL1 neuroendocrine phenotype and restore innate immune signaling (termed the "inflammatory" subtype) have durable responses to PD-L1. Some SCLCs are highly sensitive to Aurora kinase inhibitors, but early-phase trials show short-lived responses, suggesting effective therapeutic combinations are needed to increase their durability. Using immunocompetent SCLC genetically engineered mouse models (GEMMs) and syngeneic xenografts, we show durable efficacy with the combination of a highly specific Aurora A kinase inhibitor (LSN3321213) and PD-L1. LSN3321213 causes accumulation of tumor cells in mitosis with lower ASCL1 expression and higher expression of interferon target genes and antigen-presentation genes mimicking the inflammatory subtype in a cell-cycle-dependent manner. These data demonstrate that inflammatory gene expression is restored in mitosis in SCLC, which can be exploited by Aurora A kinase inhibition.</abstract><cop>United States</cop><pub>Elsevier</pub><pmid>37992688</pmid><doi>10.1016/j.xcrm.2023.101282</doi><orcidid>https://orcid.org/0000-0003-2047-0969</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2666-3791
ispartof Cell reports. Medicine, 2023-11, Vol.4 (11), p.101282, Article 101282
issn 2666-3791
2666-3791
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10694667
source ScienceDirect; Open Access: PubMed Central
subjects Animals
Aurora Kinase A - genetics
Aurora Kinase A - therapeutic use
B7-H1 Antigen - genetics
Humans
Interferons - genetics
Lung Neoplasms - drug therapy
Lung Neoplasms - genetics
Lung Neoplasms - pathology
Mice
Mitosis
Small Cell Lung Carcinoma - drug therapy
Small Cell Lung Carcinoma - genetics
Small Cell Lung Carcinoma - pathology
title Aurora A kinase inhibition induces accumulation of SCLC tumor cells in mitosis with restored interferon signaling to increase response to PD-L1
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-12T04%3A27%3A08IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Aurora%20A%20kinase%20inhibition%20induces%20accumulation%20of%20SCLC%20tumor%20cells%20in%20mitosis%20with%20restored%20interferon%20signaling%20to%20increase%20response%20to%20PD-L1&rft.jtitle=Cell%20reports.%20Medicine&rft.au=Li,%20Yixiang&rft.date=2023-11-21&rft.volume=4&rft.issue=11&rft.spage=101282&rft.pages=101282-&rft.artnum=101282&rft.issn=2666-3791&rft.eissn=2666-3791&rft_id=info:doi/10.1016/j.xcrm.2023.101282&rft_dat=%3Cproquest_pubme%3E2892948544%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c403t-9c2af0bd86def727b373a14e1bf829342b4df650cc2ce5aed82e7cdb08a6441d3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2892948544&rft_id=info:pmid/37992688&rfr_iscdi=true